Cardiac-valvular Ehlers-Danlos syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:230851OMIM:225320Q79.6
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Cardiac-valvular Ehlers-Danlos syndrome (cvEDS), also known as Ehlers-Danlos syndrome cardiac valvular type, is an extremely rare heritable connective tissue disorder characterized by severe progressive cardiac valvular problems, joint hypermobility, and skin hyperextensibility. It is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the COL1A2 gene, which encodes the pro-alpha-2 chain of type I collagen. The resulting complete absence of the pro-alpha-2(I) collagen chain leads to the production of abnormal type I collagen homotrimers composed solely of alpha-1(I) chains, which disrupts connective tissue integrity throughout the body. The hallmark feature of cvEDS is severe cardiac valvular disease, particularly affecting the aortic and mitral valves, which may progress to require surgical valve replacement. Patients typically present with joint hypermobility (both generalized and small joint), skin hyperextensibility, skin fragility with atrophic scarring, and easy bruising. Additional features may include inguinal hernias, pectus deformity, joint dislocations, and foot deformities. The cardiac valvular involvement distinguishes this subtype from other forms of Ehlers-Danlos syndrome and represents the most clinically significant and potentially life-threatening aspect of the condition. There is currently no cure or disease-specific therapy for cvEDS. Management is supportive and multidisciplinary, focusing on regular cardiac surveillance with echocardiography to monitor valvular function, surgical intervention for severe valvular insufficiency when indicated, physical therapy to support joint stability, and skin protection measures. Genetic counseling is recommended for affected families. Due to the extreme rarity of this condition, clinical experience is limited, and management guidelines are largely based on expert consensus and extrapolation from other Ehlers-Danlos syndrome subtypes.

Also known as:

Clinical phenotype terms— hover any for plain English:

Soft, doughy skinHP:0001027Hallux valgusHP:0001822Aortic root aneurysmHP:0002616
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Cardiac-valvular Ehlers-Danlos syndrome.

View clinical trials →

No actively recruiting trials found for Cardiac-valvular Ehlers-Danlos syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Cardiac-valvular Ehlers-Danlos syndrome community →

No specialists are currently listed for Cardiac-valvular Ehlers-Danlos syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Cardiac-valvular Ehlers-Danlos syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Cardiac-valvular Ehlers-Danlos syndromeForum →

No community posts yet. Be the first to share your experience with Cardiac-valvular Ehlers-Danlos syndrome.

Start the conversation →

Latest news about Cardiac-valvular Ehlers-Danlos syndrome

No recent news articles for Cardiac-valvular Ehlers-Danlos syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cardiac-valvular Ehlers-Danlos syndrome

What is Cardiac-valvular Ehlers-Danlos syndrome?

Cardiac-valvular Ehlers-Danlos syndrome (cvEDS), also known as Ehlers-Danlos syndrome cardiac valvular type, is an extremely rare heritable connective tissue disorder characterized by severe progressive cardiac valvular problems, joint hypermobility, and skin hyperextensibility. It is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in the COL1A2 gene, which encodes the pro-alpha-2 chain of type I collagen. The resulting complete absence of the pro-alpha-2(I) collagen chain leads to the production of abnormal type I collagen homotrimers composed solely of alpha-1(I

How is Cardiac-valvular Ehlers-Danlos syndrome inherited?

Cardiac-valvular Ehlers-Danlos syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.